Melanoma central nervous system metastases: current approaches, challenges, and opportunities

Pigment Cell and Melanoma Research

Volumn 29, Issue 6, 2016, Pages 627-642

  Cohen, Justine V ^a   Tawbi, Hussain ^b   Margolin, Kim A ^c   Amravadi, Ravi ^d   Bosenberg, Marcus ^a   Brastianos, Priscilla K ^e   Chiang, Veronica L ^a   de Groot, John ^b   Glitza, Isabella C ^b   Herlyn, Meenhard ^f   Holmen, Sheri L ^g   Jilaveanu, Lucia B ^a   Lassman, Andrew ^h   Moschos, Stergios ⁱ   Postow, Michael A ^j   Thomas, Reena ^k   Tsiouris, John A ^l   Wen, Patrick ^m   White, Richard M ^j   Turnham, Timothy ⁿ   Davies, Michael A ^b   Kluger, Harriet M ^a   more..

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f WISTAR INSTITUTE   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h Department of Medicine   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k STANFORD UNIVERSITY   (United States)

^l NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^m DANA FARBER CANCER INSTITUTE   (United States)

ⁿ Melanoma Research Alliance   (United States)

more..

Author keywords

brain metastasis; clinical trials; experimental models; leptomeningeal disease; tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL FEATURE; CLINICAL TRIAL; EXPERIMENTAL MODEL; HUMAN; MELANOMA; MENINX DISORDER; MOLECULARLY TARGETED THERAPY; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; STUDY DESIGN; TREATMENT RESPONSE; BRAIN TUMOR; PATHOLOGY; SECONDARY;

BRAIN NEOPLASMS; HUMANS; MELANOMA;

EID: 84995543712     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12538     Document Type: Review

References (141)

1. Agarwala, S.S., Kirkwood, J.M., Gore, M., Dreno, B., Thatcher, N., Czarnetski, B., Atkins, M., Buzaid, A., Skarlos, D., and Rankin, E.M. (2004). Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J. Clin. Oncol. 22, 2101–2107.
2. Ajithkumar, T., Parkinson, C., Fife, K., Corrie, P., and Jefferies, S. (2015). Evolving treatment options for melanoma brain metastases. Lancet Oncol. 16, e486–e497.
3. Andrews, D.W., Scott, C.B., Sperduto, P.W. et al. (2004). Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665–1672.
4. Armstrong, T.S., Mendoza, T., Gning, I., Coco, C., Cohen, M.Z., Eriksen, L., Hsu, M.A., Gilbert, M.R., and Cleeland, C. (2006). Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J. Neurooncol. 80, 27–35.
5. Azer, M.W., Menzies, A.M., Haydu, L.E., Kefford, R.F., and Long, G.V. (2014). Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib. Cancer 120, 530–536.
6. Balak, M.N., Gong, Y., Riely, G.J. et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12, 6494–6501.
7. Berghoff, A.S., Ricken, G., Widhalm, G., Rajky, O., Dieckmann, K., Birner, P., Bartsch, R., Holler, C., and Preusser, M. (2015). Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 66, 289–299.
8. Bollag, G., Hirth, P., Tsai, J. et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599.
9. Boussemart, L., Boivin, C., Claveau, J., Tao, Y.G., Tomasic, G., Routier, E., Mateus, C., Deutsch, E., and Robert, C. (2013). Vemurafenib and radiosensitization. JAMA Dermatol. 149, 855–857.
10. Brastianos, P.K., Carter, S.L., Santagata, S. et al. (2015). Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5, 1164–1177.
11. Bucheit, A.D., Chen, G., Siroy, A. et al. (2014). Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin. Cancer Res. 20, 5527–5536.
12. Busch, C., Krochmann, J., and Drews, U. (2012). Human melanoma cells in the rhombencephalon of the chick embryo: a novel model for brain metastasis. Exp. Dermatol. 21, 944–947.
13. Chamberlain, M.C. (2002). A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 94, 2675–2680.
14. Chao, J.H., Phillips, R., and Nickson, J.J. (1954). Roentgen-ray therapy of cerebral metastases. Cancer 7, 682–689.
15. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516.
16. Chen, G., and Davies, M.A. (2012). Emerging insights into the molecular biology of brain metastases. Biochem. Pharmacol. 83, 305–314.
17. Chen, G., Chakravarti, N., Aardalen, K. et al. (2014). Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin. Cancer Res. 20, 5337–5346.
18. Cho, J.H., Robinson, J.P., Arave, R.A. et al. (2015). AKT1 activation promotes development of melanoma metastases. Cell Rep. 13, 898–905.
19. Christ, S.M., Mahadevan, A., Floyd, S.R., Lam, F.C., Chen, C.C., Wong, E.T., and Kasper, E.M. (2015). Stereotactic radiosurgery for brain metastases from malignant melanoma. Surg. Neurol. Int. 6, S355–S365.
20. Clemons-Miller, A.R., Chatta, G.S., Hutchins, L., Angtuaco, E.J., Ravaggi, A., Santin, A.D., and Cannon, M.J. (2001). Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma. Clin. Cancer Res. 7, 917s–924s.
21. Cohen, J.V., Alomari, A.K., Vortmeyer, A.O., Jilaveanu, L.B., Goldberg, S.B., Mahajan, A., Chiang, V.L., and Kluger, H.M. (2016). Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol. Res. 4, 179–182.
22. Colombino, M., Capone, M., Lissia, A. et al. (2012). BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30, 2522–2529.
23. Cranmer, L.D., Trevor, K.T., Bandlamuri, S., and Hersh, E.M. (2005). Rodent models of brain metastasis in melanoma. Melanoma Res. 15, 325–356.
24. Cruz-Munoz, W., Man, S., Xu, P., and Kerbel, R.S. (2008). Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res. 68, 4500–4505.
25. Davies, M.A., Stemke-Hale, K., Lin, E. et al. (2009). Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin. Cancer Res. 15, 7538–7546.
26. Davies, M.A., Liu, P., Mcintyre, S., Kim, K.B., Papadopoulos, N., Hwu, W.J., Hwu, P., and Bedikian, A. (2011). Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117, 1687–1696.
27. De La Fuente, M., Beal, K., Carvajal, R., and Kaley, T.J. (2014). Whole-brain radiotherapy in patients with brain metastases from melanoma. CNS Oncol. 3, 401–406.
28. Di Giacomo, A.M., Ascierto, P.A., Pilla, L. et al. (2012). Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13, 879–886.
29. Di Giacomo, A.M., Ascierto, P.A., Queirolo, P. et al. (2015). Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann. Oncol. 26, 798–803.
30. Dong, Y., Richards, J.A., Gupta, R., Aung, P.P., Emley, A., Kluger, Y., Dogra, S.K., Mahalingam, M., and Wajapeyee, N. (2013). PTEN functions as a melanoma tumor suppressor by promoting host immune response. Oncogene 33, 4632–4642.
31. Dorval, T., Beuzeboc, P., Garcia-Giralt, E., Jouve, M., Palangie, T., and Pouillart, P. (1992). Malignant melanoma: treatment of metastatic meningitis with intrathecal interferon alpha-2b. Eur. J. Cancer 28, 244–245.
32. Dummer, R., Goldinger, S.M., Turtschi, C.P., Eggmann, N.B., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P.R., Felderer, L., and Rinderknecht, J.D. (2014). Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur. J. Cancer 50, 611–621.
33. Dzienis, M.R., and Atkinson, V.G. (2014). Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review. Melanoma Res. 24, 349–353.
34. Einarsdottir, B.O., Bagge, R.O., Bhadury, J. et al. (2014). Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. Oncotarget 5, 9609–9618.
35. Falchook, G.S., Long, G.V., Kurzrock, R. et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893–1901.
36. Fertil, B., and Malaise, E.P. (1985). Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int. J. Radiat. Oncol. Biol. Phys. 11, 1699–1707.
37. Fife, K.M., Colman, M.H., Stevens, G.N. et al. (2004). Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 22, 1293–1300.
38. Flanigan, J.C., Jilaveanu, L.B., Chiang, V.L., and Kluger, H.M. (2013). Advances in therapy for melanoma brain metastases. Clin. Dermatol. 31, 264–281.
39. Frenard, C., Peuvrel, L., Jean, M.S., Brocard, A., Knol, A.C., Nguyen, J.M., Khammari, A., Quereux, G., and Dreno, B. (2015). Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab. J. Neurooncol. 126, 355–360.
40. Fujimaki, T., Price, J.E., Fan, D., Bucana, C.D., Itoh, K., Kirino, T., and Fidler, I.J. (1996). Selective growth of human melanoma cells in the brain parenchyma of nude mice. Melanoma Res. 6, 363–371.
41. Fukuoka, H., Hirai, T., Okuda, T., Shigematsu, Y., Sasao, A., Kimura, E., Hirano, T., Yano, S., Murakami, R., and Yamashita, Y. (2010). Comparison of the added value of contrast-enhanced 3D fluid-attenuated inversion recovery and magnetization-prepared rapid acquisition of gradient echo sequences in relation to conventional postcontrast T1-weighted images for the evaluation of leptomeningeal diseases at 3T. AJNR Am. J. Neuroradiol. 31, 868–873.
42. Gaziel-Sovran, A., Osman, I., and Hernando, E. (2013). In vivo modeling and molecular characterization: a path toward targeted therapy of melanoma brain metastasis. Front. Oncol. 3, 127.
43. Gerstner, E.R., and Fine, R.L. (2007). Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J. Clin. Oncol. 25, 2306–2312.
44. Gingis-Velitski, S., Zetser, A., Flugelman, M.Y., Vlodavsky, I., and Ilan, N. (2004). Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J. Biol. Chem. 279, 23536–23541.
45. Glitza, I.C., Haymaker, C., Bernatchez, C. et al. (2015a). Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: a case report. Cancer Immunol. Res. 11, 1201–1206.
46. Glitza, I.C., Rohlfs, M., Bassett, R. et al. (2015b). Therapeutic outcomes of intrathecal interleukin-2 in metastatic melanoma patients with leptomeningeal disease (LMD). In Society for Neuro-Oncology Annual Meeting, San Antonio, TX.
47. Glitza, I.C., Heimberger, A.B., Sulman, E.P., and Davies, M.A. (2016). Prognostic factors for survival in melanoma patients with brain metastases. In Brain Metastases From Primary Tumors. M. Hayat, ed. (New York: Academic Press), pp. 267–292.
48. Goldberg, S.B., Gettinger, S.N., Mahajan, A. et al. (2016). Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17, 976–983.
49. Gondi, V., Pugh, S.L., Tome, W.A. et al. (2014). Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J. Clin. Oncol. 32, 3810–3816.
50. Groves, M.D. (2011). Leptomeningeal disease. Neurosurg. Clin. N. Am. 22, 67–78, vii.
51. Hanniford, D., Zhong, J., Koetz, L. et al. (2015). A miRNA-based signature detected in primary melanoma tissue predicts development of brain metastasis. Clin. Cancer Res. 21, 4903–4912.
52. Haq, R., Shoag, J., Andreu-Perez, P. et al. (2013). Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 23, 302–315.
53. Harter, P.N., Bernatz, S., Scholz, A. et al. (2015). Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget 6, 40836–40849.
54. Hauschild, A., Grob, J.J., Demidov, L.V. et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358–365.
55. Heilmann, S., Ratnakumar, K., Langdon, E.M. et al. (2015). A quantitative system for studying metastasis using transparent zebrafish. Cancer Res. 75, 4272–4282.
56. Heller, K.N., Pavlick, A.C., Hodi, F.S., Thompson, J.A., Margolin, K.A., Lawrence, D.P., Mcdermott, D.F., Samlowski, W.E., Michener, T., and Karasarides, M. (2011). Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. Meeting Proc. ASCO 29, 8581.
57. Hodi, F.S., O'day, S.J., Mcdermott, D.F. et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723.
58. Hong, J.J., Rosenberg, S.A., Dudley, M.E., Yang, J.C., White, D.E., Butman, J.A., and Sherry, R.M. (2010). Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16, 4892–4898.
59. Hottinger, A.F., Favet, L., Pache, J.C., Martin, J.B., and Dietrich, P.Y. (2011). Delayed but complete response following oral temozolomide treatment in melanoma leptomeningeal carcinomatosis. Case Rep. Oncol. 4, 211–215.
60. Huang, F.J., Steeg, P.S., Price, J.E., Chiu, W.T., Chou, P.C., Xie, K., Sawaya, R., and Huang, S. (2008). Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res. 68, 9634–9642.
61. Izraely, S., Sagi-Assif, O., Klein, A. et al. (2012). The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis. Int. J. Cancer 131, 1071–1082.
62. Jackman, D.M., Holmes, A.J., Lindeman, N., Wen, P.Y., Kesari, S., Borras, A.M., Bailey, C., De Jong, F., Jänne, P.A., and Johnson, B.E. (2006). Response and resistance in a non–small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J. Clin. Oncol. 24, 4517–4520.
63. Jilaveanu, L.B., Parisi, F., Barr, M.L. et al. (2015). PLEKHA5 as a biomarker and potential mediator of melanoma brain metastasis. Clin. Cancer Res. 21, 2138–2147.
64. Kanda, T., Ishii, K., Kawaguchi, H., Kitajima, K., and Takenaka, D. (2014). High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270, 834–841.
65. Kanda, T., Fukusato, T., Matsuda, M., Toyoda, K., Oba, H., Kotoku, J., Haruyama, T., Kitajima, K., and Furui, S. (2015). Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276, 228–232.
66. Kim, K.B., Flaherty, K.T., Chapman, P.B., Sosman, J.A., Ribas, A., Mcarthur, G.A., Amaravadi, R.K., Lee, R.J., Nolop, K.B., and Puzanov, I. (2011a). Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 29, Abstract 8519.
67. Kim, S.J., Kim, J.S., Park, E.S. et al. (2011b). Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 13, 286–298.
68. Kim, S.W., Choi, H.J., Lee, H.-J., He, J., Wu, Q., Langley, R.R., Fidler, I.J., and Kim, S.-J. (2014). Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells. Neuro Oncol. 16, 1585–1598.
69. Kim, D.W., Barcena, E., Mehta, U.N., Rohlfs, M.L., Kumar, A.J., Penas-Prado, M., and Kim, K.B. (2015). Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. BMC Cancer 15, 400.
70. Kluger, H.M., Zito, C.R., Barr, M.L., Baine, M.K., Chiang, V.L., Sznol, M., Rimm, D.L., Chen, L., and Jilaveanu, L.B. (2015). Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin. Cancer Res. 21, 3052–3060.
71. Knisely, J.P., Yu, J.B., Flanigan, J., Sznol, M., Kluger, H.M., and Chiang, V.L. (2012). Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurg. 117, 227–233.
72. Kondziolka, D., Patel, A., Lunsford, L.D., Kassam, A., and Flickinger, J.C. (1999). Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 45, 427–434.
73. Koul, D., Fu, J., Shen, R. et al. (2012). Antitumor activity of NVP-BKM120–a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin. Cancer Res. 18, 184–195.
74. Krepler, C., Xiao, M., Sproesser, K. et al. (2016). Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies. Clin. Cancer Res. 22, 1592–1602.
75. Kusters, B., Leenders, W.P., Wesseling, P., Smits, D., Verrijp, K., Ruiter, D.J., Peters, J.P., Van Der Kogel, A.J., and De Waal, R.M. (2002). Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 62, 341–345.
76. Larkin, J., Ascierto, P.A., Dreno, B. et al. (2014). Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867–1876.
77. Larkin, J., Chiarion-Sileni, V., Gonzalez, R. et al. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34.
78. Lee, H.J., Hanibuchi, M., Kim, S.-J., Yu, H., Kim, M.S., He, J., Langley, R.R., Lehembre, F., Regenass, U., and Fidler, I.J. (2016). Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. Neuro Oncol. 18, 486–496.
79. Lin, N.U., Lee, E.Q., Aoyama, H. et al. (2013a). Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 14, e396–e406.
80. Lin, N.U., Wefel, J.S., Lee, E.Q. et al. (2013b). Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 14, e407–e416.
81. Lin, N.U., Lee, E.Q., Aoyama, H. et al. (2015). Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 16, e270–e278.
82. Long, G.V., Trefzer, U., Davies, M.A. et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087–1095.
83. Long, G.V., Stroyakovskiy, D., Gogas, H. et al. (2015). Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, 444–451.
84. Maher, E.A., Mietz, J., Arteaga, C.L., Depinho, R.A., and Mohla, S. (2009). Brain metastasis: opportunities in basic and translational research. Cancer Res. 69, 6015–6020.
85. Margolin, K., Ernstoff, M.S., Hamid, O. et al. (2012). Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459–465.
86. Mathew, M., Tam, M., Ott, P.A., Pavlick, A.C., Rush, S.C., Donahue, B.R., Golfinos, J.G., Parker, E.C., Huang, P.P., and Narayana, A. (2013). Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 23, 191–195.
87. Mcdonald, R.J., Mcdonald, J.S., Kallmes, D.F., Jentoft, M.E., Murray, D.L., Thielen, K.R., Williamson, E.E., and Eckel, L.J. (2015). Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275, 772–782.
88. Mckinney, A.J., and Holmen, S.L. (2011). Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma. Chin. J. Cancer 30, 153–162.
89. Mittapalli, R.K., Vaidhyanathan, S., Dudek, A.Z., and Elmquist, W.F. (2013). Mechanisms limiting distribution of the threonine-protein kinase B-RaFV600E inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J. Pharmacol. Exp. Ther. 344, 655–664.
90. Monsma, D.J., Cherba, D.M., Eugster, E.E. et al. (2015). Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms. Am. J. Cancer Res. 5, 1507–1518.
91. Morris, S.L., Low, S.H., A'hern, R.P., Eisen, T.G., Gore, M.E., Nutting, C.M., and Harrington, K.J. (2004). A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br. J. Cancer 91, 829–833.
92. Morsi, A., Gaziel-Sovran, A., Cruz-Munoz, W., Kerbel, R.S., Golfinos, J.G., Hernando, E., and Wadghiri, Y.Z. (2013). Development and characterization of a clinically relevant mouse model of melanoma brain metastasis. Pigment Cell Melanoma Res. 26, 743–745.
93. Murry, B.P., Blust, B.E., Singh, A., Foster, T.P., and Marchetti, D. (2006). Heparanase mechanisms of melanoma metastasis to the brain: development and use of a brain slice model. J. Cell. Biochem. 97, 217–225.
94. Niessner, H., Forschner, A., Klumpp, B. et al. (2013). Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med. 2, 76–85.
95. Niessner, H., Schmitz, J., Tabatabai, G. et al. (2016). PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo. Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-0064. [Epub ahead of print].
96. Oechsle, K., Lange-Brock, V., Kruell, A., Bokemeyer, C., and De Wit, M. (2010). Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J. Cancer Res. Clin. Oncol. 136, 1729–1735.
97. Okada, H., Weller, M., Huang, R. et al. (2015). Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534–e542.
98. Papadopoulos, N., Gerber, D.L., Eton, O., and Bedikian, A.Y. (2002). The role of intrathecal (IT) use of interleukin-2 (IL-2) in the treatment of leptomeningeal disease (LMD) in patients (pts) with melanoma. Proc. Am. Soc. Clin. Oncol. 21, 353a.
99. Pape, E., Desmedt, E., Zairi, F., Baranzelli, M.C., Dziwniel, V., Dubois, F., Bonneterre, J., Mortier, L., and Le Rhun, E. (2012). Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients. In Vivo 26, 1079–1086.
100. Park, D.J., Wallick, C.J., Martyn, K.D., Lau, A.F., Jin, C., and Warn-Cramer, B.J. (2007). Akt phosphorylates Connexin43 on Ser373, a “mode-1” binding site for 14-3-3. Cell Commun. Adhes. 14, 211–226.
101. Park, E.S., Kim, S.J., Kim, S.W. et al. (2011). Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc. Natl Acad. Sci. USA 108, 17456–17461.
102. Patchell, R.A., Tibbs, P.A., Walsh, J.W., Dempsey, R.J., Maruyama, Y., Kryscio, R.J., Markesbery, W.R., Macdonald, J.S., and Young, B. (1990). A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322, 494–500.
103. Patchell, R.A., Tibbs, P.A., Regine, W.F., Dempsey, R.J., Mohiuddin, M., Kryscio, R.J., Markesbery, W.R., Foon, K.A., and Young, B. (1998). Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485–1489.
104. Patel, K.R., Shoukat, S., Oliver, D.E., Chowdhary, M., Rizzo, M., Lawson, D.H., Khosa, F., Liu, Y., and Khan, M.K. (2015). Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am. J. Clin. Oncol. doi: 10.1097/COC.0000000000000199. [Epub ahead of print].
105. Peng, W., Chen, J.Q., Liu, C. et al. (2016). Loss of PTEN promotes resistance to T-cell mediated immunotherapy. Cancer Discov. 6, 201–216.
106. Perez-Rodriguez, J., Lai, S., Ehst, B.D., Fine, D.M., and Bluemke, D.A. (2009). Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment–report of 33 cases. Radiology 250, 371–377.
107. Perissinotti, A.J., and Reeves, D.J. (2010). Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann. Pharmacother. 44, 1633–1640.
108. Postow, M.A., Callahan, M.K., Barker, C.A. et al. (2012). Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925–931.
109. Prince, M.R., Zhang, H., Morris, M., Macgregor, J.L., Grossman, M.E., Silberzweig, J., Delapaz, R.L., Lee, H.J., Magro, C.M., and Valeri, A.M. (2008). Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248, 807–816.
110. Qian, J.M., Yu, J.B., Kluger, H.M., and Chiang, V.L. (2016). Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122, 3051–3058.
111. Quant, E.C., and Wen, P.Y. (2011). Response assessment in neuro-oncology. Curr. Oncol. Rep. 13, 50–56.
112. Raizer, J.J., Hwu, W.J., Panageas, K.S. et al. (2008). Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 10, 199–207.
113. Raub, T.J., Wishart, G.N., Kulanthaivel, P., Staton, B.A., Ajamie, R.T., Sawada, G.A., Gelbert, L.M., Shannon, H.E., Sanchez-Martinez, C., and De Dios, A. (2015). Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab. Dispos. 43, 1360–1371.
114. Rebecca, V.W., and Amaravadi, R.K. (2016). Emerging strategies to effectively target autophagy in cancer. Oncogene 35, 1–11.
115. Ribas, A., Puzanov, I., Dummer, R. et al. (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908–918.
116. Robert, C., Thomas, L., Bondarenko, I. et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526.
117. Robert, C., Karaszewska, B., Schachter, J. et al. (2015a). Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30–39.
118. Robert, C., Schachter, J., Long, G.V. et al. (2015b). Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532.
119. Salmaggi, A., Silvani, A., Eoli, M., Lamperti, E., and Boiardi, A. (2002). Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report. Neurol. Sci 23, 257–258.
120. Sampson, J.H., Carter, J.H. Jr, Friedman, A.H., and Seigler, H.F. (1998). Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88, 11–20.
121. Schaefer, N., Rasch, K., Moehlenbruch, M., Urbach, H., Stuplich, M., Blasius, E., Scheffler, B., Herrlinger, U., and Glas, M. (2011). Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine. Acta Oncol. 50, 1260–1262.
122. Segura, P.P., Gil, M., Balana, C., Chacon, I., Langa, J.M., Martin, M., and Bruna, J. (2012). Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. J. Neurooncol. 109, 137–142.
123. Seifert, H., Hirata, E., Gore, M., Khabra, K., Messiou, C., Larkin, J., and Sahai, E. (2016). Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. Pigment Cell Melanoma Res. 29, 92–100.
124. Shonka, N.A., Kessinger, A.M., and Aizenberg, M.R. (2014). Intrathecal interleukin-2 for melanomatous meningitis. J. Clin. Oncol. 32, e111–e113.
125. Skibber, J.M., Soong, S.J., Austin, L., Balch, C.M., and Sawaya, R.E. (1996). Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann. Surg. Oncol. 3, 118–123.
126. Sosman, J.A., Pavlick, A.C., Schuchter, L.M. et al. (2012). Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAF V600E melanoma. J. Clin. Oncol. 30, 8503.
127. Sundstrom, T., Daphu, I., Wendelbo, I. et al. (2013). Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis model. Cancer Res. 73, 2445–2456.
128. Tekle, C., Nygren, M.K., Chen, Y.W., Dybsjord, I., Nesland, J.M., Maelandsmo, G.M., and Fodstad, O. (2012). B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int. J. Cancer 130, 2282–2290.
129. Thavarajah, N., Bedard, G., Zhang, L. et al. (2014). Psychometric validation of the functional assessment of cancer therapy–brain (FACT-Br) for assessing quality of life in patients with brain metastases. Support. Care Cancer 22, 1017–1028.
130. Umansky, V., and Sevko, A. (2013). Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells. Pigment Cell Melanoma Res. 26, 457–463.
131. Vogt, P.K., and Hart, J.R. (2011). PI3K and STAT3: a new alliance. Cancer Discov. 1, 481–486.
132. Weber, J., Thompson, J.A., Hamid, O. et al. (2009). A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15, 5591–5598.
133. Weber, J.S., Amin, A., Minor, D., Siegel, J., Berman, D., and O'day, S.J. (2011). Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. 21, 530–534.
134. Weber, J.S., D'angelo, S.P., Minor, D. et al. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375–384.
135. Werner-Klein, M., Proske, J., Werno, C. et al. (2014). Immune humanization of immunodeficient mice using diagnostic bone marrow aspirates from carcinoma patients. PLoS ONE 9, e97860.
136. Wilgenhof, S., and Neyns, B. (2014). Complete cytologic remission of V600E BRAF-mutant melanoma-associated leptomeningeal carcinomatosis upon treatment with dabrafenib. J. Clin. Oncol. 33, 109–111.
137. Xie, T.X., Huang, F.J., Aldape, K.D., Kang, S.H., Liu, M., Gershenwald, J.E., Xie, K., Sawaya, R., and Huang, S. (2006). Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 66, 3188–3196.
138. Yaeh, A., Nanda, T., Jani, A. et al. (2015). Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery. J. Neurooncol. 124, 507–514.
139. Yano, S., Shinohara, H., Herbst, R.S., Kuniyasu, H., Bucana, C.D., Ellis, L.M., Davis, D.W., Mcconkey, D.J., and Fidler, I.J. (2000). Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 60, 4959–4967.
140. Zhang, C., Zhang, F., Tsan, R., and Fidler, I.J. (2009). Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. Cancer Res. 69, 828–835.
141. Zhang, L., Zhang, S., Yao, J. et al. (2015). Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527, 100–104.